Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 24, 2025
Daily News
June 24, 2025
- Japan Sets June 26 for First Meeting of Public-Private Council for Biopharmaceutical Innovation
June 24, 2025
- Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
- FPMAJ Chair Questions Sakigake as Incentive for Prioritizing Japan R&D
June 24, 2025
- Keytruda Label Update Unlocks First New Treatment in 14 Years for HER2-Positive Gastric Cancer: Oncologist
June 24, 2025
- Axcelead, Superluminal Pair Up to Target Challenging Molecular Mechanisms
June 24, 2025
- Otsuka Bags Rights to Bispecific T-Cell Engager from China’s Harbour
June 24, 2025
- Ono Snags Japan, Korea Rights to Vertex’s Povetacicept
June 24, 2025
- MHLW Survey Flags Low Rate of Unit Price-Based Deals When Agents Involved
June 24, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…